Zobrazeno 1 - 10
of 10
pro vyhledávání: '"Scott L. Ackler"'
Autor:
Steven W. Elmore, Chris Tse, Joel D. Leverson, Deepak Sampath, Heather Maecker, Saul H. Rosenberg, Scott L. Ackler, Haichao Zhang, Stephen K. Tahir, Alexander R. Shoemaker, Yu Shen, Morey Smith, Xiaoyu Lin, Paul Nimmer, Michael J. Mitten, Bernard Liu, Xiaoli Huang, Vivek Abraham, Sha Jin, Jun Chen
PDF file - 40K
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::bd2c37b6b6dd801b591e2466ba9d48a4
https://doi.org/10.1158/1535-7163.22497208
https://doi.org/10.1158/1535-7163.22497208
Autor:
Steven W. Elmore, Chris Tse, Joel D. Leverson, Deepak Sampath, Heather Maecker, Saul H. Rosenberg, Scott L. Ackler, Haichao Zhang, Stephen K. Tahir, Alexander R. Shoemaker, Yu Shen, Morey Smith, Xiaoyu Lin, Paul Nimmer, Michael J. Mitten, Bernard Liu, Xiaoli Huang, Vivek Abraham, Sha Jin, Jun Chen
PDF file - 78K
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::70cb83ab1dce91e1962e4cf133b54b8a
https://doi.org/10.1158/1535-7163.22497211
https://doi.org/10.1158/1535-7163.22497211
Autor:
Steven W. Elmore, Chris Tse, Joel D. Leverson, Deepak Sampath, Heather Maecker, Saul H. Rosenberg, Scott L. Ackler, Haichao Zhang, Stephen K. Tahir, Alexander R. Shoemaker, Yu Shen, Morey Smith, Xiaoyu Lin, Paul Nimmer, Michael J. Mitten, Bernard Liu, Xiaoli Huang, Vivek Abraham, Sha Jin, Jun Chen
PDF file - 77K
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4246d1fdcd63851c0714efa3d05f46d0
https://doi.org/10.1158/1535-7163.22497205.v1
https://doi.org/10.1158/1535-7163.22497205.v1
ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets
Autor:
Jackie Lee, Darren C. Phillips, Sha Jin, Morey L. Smith, Yu Xiao, Heather Maecker, Nathaniel D. Catron, Saul H. Rosenberg, David C.S. Huang, Michael J. Mitten, John F. Seymour, Anatol Oleksijew, Stephen K. Tahir, Andrew J. Souers, Peter Kovar, Kylie D. Mason, Gerard M. Sullivan, Lloyd T. Lam, Chang H. Park, Sarah G. Hymowitz, Jun Chen, Scott L. Ackler, Steven W. Elmore, Rod A. Humerickhouse, Brian D. Dayton, Andrew W. Roberts, Cheol-Min Park, Sari H. Enschede, Haichao Zhang, Hong Ding, Wayne J. Fairbrother, John Xue, Kennan C. Marsh, Seong Lin Khaw, Deepak Sampath, Erwin R. Boghaert, Chris Tse, Paul Nimmer, Michael D. Wendt, Joel D. Leverson
Publikováno v:
Nature Medicine. 19:202-208
Proteins in the B cell CLL/lymphoma 2 (BCL-2) family are key regulators of the apoptotic process. This family comprises proapoptotic and prosurvival proteins, and shifting the balance toward the latter is an established mechanism whereby cancer cells
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ad0d8497b8cfd427f85db3ecd891b9c2
https://doi.org/10.1038/nm.3048
https://doi.org/10.1038/nm.3048
Autor:
Michael J. Mitten, Anatol Oleksijew, Steven W. Elmore, Scott L. Ackler, Marion Refici, David Frost, Christin Tse, Stephen K. Tahir, Kelly Foster, Saul H. Rosenberg, Stephen W. Fesik, Yu Xiao, Alexander R. Shoemaker
Publikováno v:
Cancer Chemotherapy and Pharmacology. 66:869-880
This study was designed to test the ability of the Bcl-2 family inhibitor ABT-263 to potentiate commonly used chemotherapeutic agents and regimens in hematologic tumor models. Models of B-cell lymphoma and multiple myeloma were tested in vitro and in
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::37f07ae40b84246363073e2ca4c8581b
https://doi.org/10.1007/s00280-009-1232-1
https://doi.org/10.1007/s00280-009-1232-1
Autor:
Scott L. Ackler, Saul H. Rosenberg, Joy Bauch, Sally Schlessinger, Marion Refici, Kelly Foster, Christin Tse, Sanjay R. Chemburkar, Anatol Oleksijew, David Frost, Michael J. Mitten, Baole Wang, Alex R. Shoemaker, Stephen W. Fesik, Steven W. Elmore, Yu Xiao
Publikováno v:
Molecular Cancer Therapeutics. 7:3265-3274
ABT-263 is a potent, orally bioavailable inhibitor of the antiapoptotic Bcl-2 family members Bcl-2, Bcl-xL, and Bcl-w, which is currently in phase I clinical trials. Previous work has shown that this compound has low nanomolar cell-killing activity i
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::00074da8c7e1833f3576f6f572622970
https://doi.org/10.1158/1535-7163.mct-08-0268
https://doi.org/10.1158/1535-7163.mct-08-0268
Activity of the Bcl-2 Family Inhibitor ABT-263 in a Panel of Small Cell Lung Cancer Xenograft Models
Autor:
Baole Wang, Joy Bauch, David Frost, Christin Tse, Steven K. Tahir, Kennan C. Marsh, Xiufen Yang, Anatol Oleksijew, Jacqueline M. O'Connor, Debra Ferguson, Michael J. Mitten, Stephen W. Fesik, Scott L. Ackler, Saul H. Rosenberg, Jessica Adickes, Alex R. Shoemaker, Steven W. Elmore, Marion Refici
Publikováno v:
Clinical Cancer Research. 14:3268-3277
Purpose: The purpose of this study was to characterize the activity of the Bcl-2 protein family inhibitor ABT-263 in a panel of small cell lung cancer (SCLC) xenograft models. Experimental Design: A panel of 11 SCLC xenograft models was established t
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::fbf3f2ccf1c68a0d7d6f46575e0ec70e
https://doi.org/10.1158/1078-0432.ccr-07-4622
https://doi.org/10.1158/1078-0432.ccr-07-4622
Autor:
Kelly Foster, Anatol Oleksijew, Jonathan Hickson, Jerry Clarin, Sally Schlessinger, Erwin R. Boghaert, Sasmita Mishra, Jun Chen, Stephen K. Tahir, Scott L. Ackler, Andrew J. Souers, Brenda Chyla, Joel D. Leverson, Thomas McGonigal, Morey L. Smith
Publikováno v:
Pharmacology Research & Perspectives
The Bcl-2 family inhibitors venetoclax and navitoclax demonstrated potent antitumor activity in chronic lymphocytic leukemia patients, notably in reducing marrow load and adenopathy. Subsequent trials with venetoclax have been initiated in non-Hodgki
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ce3772111f39b28b66da484405529a70
https://pubmed.ncbi.nlm.nih.gov/26516589
https://pubmed.ncbi.nlm.nih.gov/26516589
Autor:
Alexander R. Shoemaker, Chris Tse, Xiaoli Huang, Vivek C. Abraham, Paul Nimmer, Deepak Sampath, Scott L. Ackler, Steven W. Elmore, Stephen K. Tahir, Saul H. Rosenberg, Michael J. Mitten, Morey L. Smith, Bernard Liu, Joel D. Leverson, Yu Shen, Xiaoyu Lin, Sha Jin, Heather Maecker, Jun Chen, Haichao Zhang
Publikováno v:
Molecular cancer therapeutics. 10(12)
The ability of a cancer cell to avoid apoptosis is crucial to tumorigenesis and can also contribute to chemoresistance. The Bcl-2 family of prosurvival proteins (Bcl-2, Bcl-XL, Bcl-w, Mcl-1, and A1) plays a key role in these processes. We previously
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::02c7a5f11df1beabc11b148daa978c85
https://pubmed.ncbi.nlm.nih.gov/21914853
https://pubmed.ncbi.nlm.nih.gov/21914853
Autor:
Baole Wang, Mary K. Joseph, Haichao Zhang, Alex R. Shoemaker, Steven W. Elmore, Paul Nimmer, David Frost, Michael J. Mitten, Anatol Oleksijew, Stephen W. Fesik, Yu Xiao, Jacqeuline M. O’Connor, Christin Tse, Scott L. Ackler, Saul H. Rosenberg
Publikováno v:
Blood. 108:825-825
ABT-263 is an orally bioavailable small molecule inhibitor of Bcl-2 family proteins with a Ki of ≤ 1 nM against Bcl-2, Bcl-XL, and Bcl-w. Non-Hodgkin’s B-cell lymphomas represent clinically relevant disease targets for this molecule due, in part,
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::f67a9d0265a33b721b52232e6dc6d8ce
https://doi.org/10.1182/blood.v108.11.825.825
https://doi.org/10.1182/blood.v108.11.825.825